
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 224 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 30 results:
Author Title Type [ Year
Filters: Author is Gallagher, A. M. [Clear All Filters]
“The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations”, Pharmacoepidemiol Drug Saf, 2019.
, “Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies”, Pharmacoepidemiol Drug Saf, 2019.
“Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing”, PLoS One, vol. 14, p. e0218115, 2019.
, , “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
, “A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)”, Clin Epidemiol, vol. 10, pp. 299-310, 2018.
, “Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study”, Drugs Real World Outcomes, 2018.
, “Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Eur J Clin Pharmacol, vol. 73, pp. 115-123, 2017.
“Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes”, BMJ Open Diabetes Res Care, vol. 5, p. e000400, 2017.
, “Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs”, Pharmacoepidemiol Drug Saf, 2017.
“Comparability of the age and sex distribution of the UK Clinical Practice Research Datalink and the total Dutch population”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1460-1464, 2016.
, “The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism”, PLoS One, vol. 11, p. e0148349, 2016.
, “Data Resource Profile: Clinical Practice Research Datalink (CPRD)”, Int J Epidemiol, vol. 44, pp. 827-36, 2015.
, “Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs”, BMC Pharmacol Toxicol, vol. 16, p. 8, 2015.
“Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 999-1003, 2015.
“Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes”, BMJ Open, vol. 4, p. e003839, 2014.
, “Cancer recording and mortality in the General Practice Research Database and linked cancer registries”, Pharmacoepidemiol Drug Saf, vol. 22, pp. 168-75, 2013.
, “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
, “Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data”, Diabetologia, vol. 55, pp. 654-65, 2012.
, “Quality of INR control and outcomes following venous thromboembolism”, Clin Appl Thromb Hemost, vol. 18, pp. 370-8, 2012.
, “Resource utilization and outcomes in patients with atrial fibrillation: a case control study”, Appl Health Econ Health Policy, vol. 10, pp. 249-59, 2012.
, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
, “Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients”, Thromb Haemost, vol. 106, pp. 968-77, 2011.
, “How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database”, Thromb Haemost, vol. 101, pp. 527-34, 2009.
, “Risk markers for both chronic fatigue and irritable bowel syndromes: a prospective case-control study in primary care”, Psychol Med, vol. 39, pp. 1913-21, 2009.
, , “Fracture outcomes related to persistence and compliance with oral bisphosphonates”, J Bone Miner Res, vol. 23, pp. 1569-75, 2008.
, “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?”, J Thromb Haemost, vol. 6, pp. 1500-6, 2008.
, “The prognosis of different fatigue diagnostic labels: a longitudinal survey”, Fam Pract, vol. 22, pp. 383-8, 2005.
, “Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001”, J R Soc Med, vol. 97, pp. 571-5, 2004.
,